ArticleNature2022
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
Abstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,320 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,320citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,320 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical effects of ursodeoxycholic acid in COVID-19 infection: a systematic review and dose-response meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.The Lancet. Infectious diseases · 2026Trial
- CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 disease.Scientific reports · 2025Trial
- Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants.Antimicrobial agents and chemotherapy · 2025Trial
- Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains.Emerging microbes & infections · 2026Article
- Broad cross-T cell immunity between emerging SARS-CoV-2 serotypes waved by spike-signature mutations.Emerging microbes & infections · 2026Article
- Serology survey against multiple SARS-CoV-2 variants of residents in Tainan, Taiwan.Virulence · 2026Article
- Receptor binding domain-independent pancoronavirus vaccine design by fusion of conserved T/B Epitopes.Emerging microbes & infections · 2026Article
- Safety, Pharmacokinetics, and Predicted Neutralizing Activity of the SARS-CoV-2 Monoclonal Antibody Sipavibart: Results from Little DIPPER and the SUPERNOVA Substudy.Infectious diseases and therapy · 2026Article
- Disulfide bonds stabilize the SARS-CoV-2 RBD and preserve binding to ACE2 following thermal denaturation.Bioscience reports · 2026Article
- Targeting of conserved spike epitopes enables broad antibody neutralisation of diverse bat sarbecoviruses.PLoS biology · 2026Article
- Nanobodies targeting SARS-CoV-2 papain-like protease exert dual antiviral and anti-inflammatory effects.Journal of virology · 2026Article
- mRNA Vaccines Targeting the Conserved SARS-CoV-2 Fusion Machinery Elicit Cross-Variant and Robust Immunity.Vaccines · 2026Article
- Article
- Review
- Extracellular Vesicles as Molecular Regulators of Viral Infection: Implications for COVID-19 and Future Viral Pandemics.Current issues in molecular biology · 2026Review
- Dissociation kinetics and avidity gate SARS-CoV-2 neutralization by HR2 stem helix antibodies.bioRxiv : the preprint server for biology · 2026Article
- Dynamics of neutralizing antibody responses after trivalent XBB.1.5 booster vaccination: a 480-day longitudinal study.Signal transduction and targeted therapy · 2026Article
- R1-32-like public antibodies acquire tolerance to SARS-CoV-2 antigenic drift through somatic hypermutation.PLoS biology · 2026Article
- Serum Escape Landscape of SARS-CoV-2 Omicron JN.1 and XEC RBD Under COVID-19 Vaccine Breakthrough Immunity in China.Microorganisms · 2026Article
1,260 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
30 authors.
Yunlong Cao *Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China. yunlongcao@pku.edu.cn.ORCID http://orcid.org/0000-0001-5918-1078
Jing Wang *Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.ORCID http://orcid.org/0000-0002-9084-9985
Fanchong Jian *Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.ORCID http://orcid.org/0000-0001-8703-3507
Tianhe Xiao *Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Weiliang Song *Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Ayijiang Yisimayi *Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Weijin Huang *Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.ORCID http://orcid.org/0000-0002-4246-8889
Qianqian LiDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.
Peng WangBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Ran AnBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Jing WangBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Yao WangBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Xiao NiuBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Sijie YangBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Hui LiangBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Haiyan SunBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Tao LiDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.
Yuanling YuDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.
Qianqian CuiDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.
Shuo LiuDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.
Xiaodong YangBeijing YouAn Hospital, Capital Medical University, Beijing, P. R. China.
Shuo DuSchool of Life Sciences, Peking University, Beijing, P. R. China.ORCID http://orcid.org/0000-0003-0936-0785
Zhiying ZhangSchool of Life Sciences, Peking University, Beijing, P. R. China.ORCID http://orcid.org/0000-0002-5690-9796
Xiaohua HaoBeijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.
Fei ShaoBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Ronghua JinBeijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.
Xiangxi WangCAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, P. R. China. xiangxi@ibp.ac.cn.
Junyu XiaoBeijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, P. R. China. junyuxiao@pku.edu.cn.ORCID http://orcid.org/0000-0003-1822-1701
Youchun WangDivision of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China. wangyc@nifdc.org.cn.ORCID http://orcid.org/0000-0001-9769-5141
Xiaoliang Sunney XieBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China. sunneyxie@biopic.pku.edu.cn.ORCID http://orcid.org/0000-0001-9281-5239
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 B.1.1.529 (Omicron) variant contains 15 mutations of the receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies requires immediate investigation. Here we use high-throughput yeast display screening
Indexed as
Neutralization TestsAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCells, CulturedConvalescenceCOVID-19COVID-19 VaccinesEpitopes, B-LymphocyteHumansImmune EvasionImmune SeraModels, MolecularMutationSARS-CoV-2ACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesEpitopes, B-LymphocyteImmune SeraSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.